We are live on !
Find out more
Paradigm Biocapital Advisors Portfolio holdings
AUM
$5.34B
Turnover
50%
1-Year Est. Return
380.18%
This Fund
S&P 500
This Quarter Est. Return
+40.65%
1 Year Est. Return
+380.18%
3 Year Est. Return
+803.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.34B
AUM Growth
+$446M
(+9.1%)
Cap. Flow
-$643M
Cap. Flow % of AUM
Cap. Flow %
-12.03%
Top 10 Holdings %
Top 10 Hldgs %
75.21%
Holding
42
New
7
Increased
12
Reduced
7
Closed
14
Avg Time Held
1.1
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$145M |
| 2 |
Spyre Therapeutics
SYRE
|
+$137M |
| 3 |
Genmab
GMAB
|
+$137M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$98.3M |
| 5 |
MBX Biosciences
MBX
|
+$87.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcellx
ACLX
|
+$663M |
| 2 |
Vaxcyte
PCVX
|
+$145M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$142M |
| 4 |
Terns Pharmaceuticals
TERN
|
+$117M |
| 5 |
Cytokinetics
CYTK
|
+$97.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$40.1B
| $1.19B | 22.31% |
6,361,323
-294,380
| -4% | -$43M |
2024 Q1
9 quarters
|
|
2
DELISTED
Nuvalent
NUVL
| $732M | 13.7% |
5,924,433
+600,000
| +11% | +$64.5M |
2023 Q2
12 quarters
|
|
|
3
Edgewise Therapeutics
EWTX
$4.27B
| $415M | 7.77% |
10,215,455
+2,850,417
| +39% | +$98.3M |
2024 Q1
9 quarters
|
|
|
4
Genmab
GMAB
$26.9B
| $361M | 6.76% |
13,133,131
+5,165,295
| +65% | +$137M |
2025 Q3
3 quarters
|
|
|
5
Spyre Therapeutics
SYRE
$8.44B
| $341M | 6.38% |
3,840,778
+1,883,512
| +96% | +$137M |
2024 Q3
7 quarters
|
|
6
DELISTED
Apogee Therapeutics
APGE
| $209M | 3.92% |
1,576,385
+228,142
| +17% | +$20.6M |
2024 Q1
9 quarters
|
|
7
Oruka Therapeutics
ORKA
$5.31B
| $204M | 3.82% |
2,144,526
-175,790
| -8% | -$11.7M |
2025 Q4
2 quarters
|
|
8
Tango Therapeutics
TNGX
$3.94B
| $199M | 3.72% |
6,357,523
+2,347,844
| +59% | +$58M |
2026 Q1
1 quarter
|
|
9
Belite Bio
BLTE
$5.93B
| $190M | 3.55% |
1,232,877
+118,093
| +11% | +$18.1M |
2026 Q1
1 quarter
|
|
10
Erasca
ERAS
$5.03B
| $175M | 3.28% |
9,550,000
-842,702
| -8% | -$12.1M |
2024 Q2
8 quarters
|
|
11
Tarsus Pharmaceuticals
TARS
$3.19B
| $175M | 3.27% |
2,775,649
+213,495
| +8% | +$13.6M |
2023 Q4
10 quarters
|
|
|
12
Alnylam Pharmaceuticals
ALNY
$30B
| $144M | 2.71% |
+480,000
| New | +$145M |
2026 Q2
0 quarters
|
|
13
Insmed
INSM
$20.4B
| $141M | 2.65% |
1,325,977
+71,489
| +6% | +$8.66M |
2026 Q1
1 quarter
|
|
|
14
MBX Biosciences
MBX
$2.34B
| $138M | 2.59% |
+2,508,015
| New | +$87.6M |
2026 Q2
0 quarters
|
|
|
15
Vaxcyte
PCVX
$9.5B
| $124M | 2.32% |
2,127,852
-2,665,168
| -56% | -$145M |
2024 Q1
9 quarters
|
|
16
Viridian Therapeutics
VRDN
$2.53B
| $124M | 2.31% |
6,723,788
+3,574,895
| +114% | +$57.6M |
2021 Q4
18 quarters
|
|
17
Olema Pharmaceuticals
OLMA
$561M
| $108M | 2.03% |
8,670,576
+650,000
| +8% | +$8.71M |
2023 Q1
13 quarters
|
|
18
Jade Biosciences
JBIO
$928M
| $63.5M | 1.19% |
+2,857,405
| New | +$59.6M |
2026 Q2
0 quarters
|
|
19
Tyra Biosciences
TYRA
$1.41B
| $58.4M | 1.09% |
1,828,607
-226,384
| -11% | -$7.49M |
2026 Q1
1 quarter
|
|
20
Assembly Biosciences
ASMB
$404M
| $42.7M | 0.8% |
1,553,748
+888,497
| +134% | +$24.2M |
2025 Q4
2 quarters
|
|
21
EyePoint Inc
EYPT
$34.9M
| $41.3M | 0.77% |
2,890,397
-252,040
| -8% | -$3.37M |
2025 Q3
3 quarters
|
|
22
Achieve Life Sciences
ACHV
$669M
| $32.3M | 0.61% |
+4,951,856
| New | +$23.6M |
2026 Q2
0 quarters
|
|
23
Vor Biopharma
VOR
$1.08B
| $32.2M | 0.6% |
1,750,000
| – | – |
2025 Q4
2 quarters
|
|
24
MapLight Therapeutics
MPLT
$443M
| $24.6M | 0.46% |
+685,852
| New | +$19.7M |
2026 Q2
0 quarters
|
|
|
KARD
25
Kardigan Inc
KARD
$1.2B
| $21.5M | 0.4% |
+900,000
| New | +$20.8M |
2026 Q2
0 quarters
|
|
Similar funds
MA
Paradigm Biocapital Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Paradigm Biocapital Advisors held 42 positions worth $5.34B, up 9.1% from $4.89B the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Paradigm Biocapital Advisors withdrew a net $643M in Q2 2026, closing 14 positions and reducing 7 holdings. Its most notable exit was Arcellx, an estimated $663M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Paradigm Biocapital Advisors opened a new position in Alnylam Pharmaceuticals worth $144M.
- Paradigm Biocapital Advisors's largest Q2 2026 buy was Alnylam Pharmaceuticals: 480,000 shares worth $144M.
- Paradigm Biocapital Advisors added most to Spyre Therapeutics in Q2 2026, an estimated $137M increase.
- Paradigm Biocapital Advisors's biggest Q2 2026 reduction was Vaxcyte, cutting an estimated $145M.
- Paradigm Biocapital Advisors fully exited Arcellx in Q2 2026, selling an estimated $663M.
- Paradigm Biocapital Advisors's ten largest holdings make up 75% of its $5.34B portfolio in Q2 2026.
- Paradigm Biocapital Advisors opened 7 new positions and closed 14 in Q2 2026.
- Paradigm Biocapital Advisors's portfolio value rose 9.1% quarter-over-quarter to $5.34B.
Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.